Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 12/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927203 | 0.85 | CHRM1 (0.48) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL5927082 | 0.78 | ITGB1 (0.50) | ERAP1ITGB1ITGA4PDK1PDK2 | |
| SCHEMBL5926657 | 0.77 | ERAP1 (0.48) | ERAP1ITGB1ITGA4NHERF1PYGL | |
| SCHEMBL5927209 | 0.76 | ITGB1 (0.55) | ITGB1ITGA4NHERF1PYGLPDK1 | |
| SCHEMBL5926900 | 0.75 | ITGB1 (0.47) | ERAP1ITGB1ITGA4NHERF1PYGL | |
| SCHEMBL8340240 | 0.75 | KCNA5 (0.60) | ITGB1ITGA4 | |
| SCHEMBL5926755 | 0.75 | KCNA5 (0.60) | ITGB1ITGA4 | |
| SCHEMBL5926681 | 0.75 | ERAP1 (0.53) | ERAP1ITGB1ITGA4NHERF1PYGL | |
| SCHEMBL5927573 | 0.73 | ITGA4 (0.45) | ERAP1ITGB1ITGA4 | |
| SCHEMBL5926298 | 0.73 | ITGA4 (0.47) | ERAP1ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CHRM1 2567/4885CHRM2 2156/4885CHRM4 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.